Sarepta Therapeutics’ (SRPT) Sell Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their sell rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note released on Monday, MarketBeat reports. They currently have a $5.00 price target on the biotechnology company’s stock.

A number of other equities analysts have also weighed in on the stock. Zacks Research upgraded shares of Sarepta Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Wolfe Research upgraded Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a research note on Thursday, July 9th. William Blair raised Sarepta Therapeutics to a “hold” rating in a report on Wednesday, September 23rd. Wall Street Zen cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Benchmark reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a report on Wednesday, September 9th. Seven research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and eight have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $22.71.

Sarepta Therapeutics Stock Up 1.1%

NASDAQ:SRPT opened at $17.50 on Monday. The firm has a market cap of $1.85 billion, a P/E ratio of -6.03, a P/E/G ratio of 0.27 and a beta of 0.38. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. Sarepta Therapeutics has a fifty-two week low of $14.68 and a fifty-two week high of $25.32. The firm has a 50-day simple moving average of $19.10 and a two-hundred day simple moving average of $18.82.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The firm had revenue of $401.25 million for the quarter, compared to the consensus estimate of $366.39 million. During the same quarter in the prior year, the firm posted $2.02 earnings per share. The business’s revenue was down 34.3% on a year-over-year basis. Analysts predict that Sarepta Therapeutics will post 3.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tidal Investments LLC purchased a new stake in Sarepta Therapeutics during the 2nd quarter valued at $183,000. Baird Financial Group Inc. lifted its holdings in shares of Sarepta Therapeutics by 7.6% during the 2nd quarter. Baird Financial Group Inc. now owns 12,805 shares of the biotechnology company’s stock valued at $230,000 after buying an additional 901 shares during the period. Nykredit A S purchased a new position in shares of Sarepta Therapeutics in the 2nd quarter worth $43,000. Corient Private Wealth LP boosted its stake in shares of Sarepta Therapeutics by 273.4% in the 2nd quarter. Corient Private Wealth LP now owns 36,712 shares of the biotechnology company’s stock worth $660,000 after buying an additional 26,880 shares during the last quarter. Finally, Amundi bought a new stake in shares of Sarepta Therapeutics in the second quarter worth $350,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs include RNA-based therapies, gene therapy and other genetic medicine approaches designed to address the underlying causes of serious genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for certain patients with DMD mutations, as well as Elevidys, a gene therapy for eligible patients with Duchenne muscular dystrophy.